Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$11.86
-0.3%
$13.29
$10.45
$21.69
$4.19B0.58651,149 shs899,698 shs
Glaukos Co. stock logo
GKOS
Glaukos
$92.21
-2.6%
$94.30
$77.10
$163.71
$5.27B0.83681,471 shs901,865 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$83.28
+1.0%
$84.06
$71.42
$109.58
$1.88B0.86162,931 shs195,604 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€24.42
+3.2%
€21.30
€16.56
€24.90
$7.40B0.51350,972 shs374,000 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-0.38%+8.77%+4.13%-27.95%-19.81%
Glaukos Co. stock logo
GKOS
Glaukos
-2.49%+5.39%+2.40%-35.88%-14.97%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+0.99%+1.45%+0.56%-13.54%+9.28%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+3.30%+14.97%+11.86%+21.92%+8.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
4.3036 of 5 stars
4.14.00.00.02.60.03.8
Glaukos Co. stock logo
GKOS
Glaukos
4.6847 of 5 stars
4.42.00.04.44.12.50.6
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
3.254 of 5 stars
2.32.03.30.03.43.31.3
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.0161 of 5 stars
0.01.01.70.02.70.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.25
Hold$15.5030.69% Upside
Glaukos Co. stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6746.04% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.63
Moderate Buy$98.1417.85% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest LMAT, STVN, BLCO, and GKOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/6/2025
Glaukos Co. stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/2/2025
Glaukos Co. stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $12.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $15.50
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$140.00 ➝ $135.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$140.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$176.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.83B0.87$1.41 per share8.41$18.57 per share0.64
Glaukos Co. stock logo
GKOS
Glaukos
$404.52M13.03N/AN/A$9.46 per share9.75
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$226.26M8.32$1.47 per share56.52$13.38 per share6.22
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$1.10B6.70€1.02 per share23.97€4.15 per share5.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A12.350.85-6.62%3.35%1.66%7/30/2025 (Estimated)
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$30.10M$1.9845.5138.382.2219.40%13.15%11.47%N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$157.62M€0.5151.9642.107.1810.47%9.86%5.79%N/A

Latest LMAT, STVN, BLCO, and GKOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.50$0.48-$0.02$0.48$57.61 million$59.87 million
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
Glaukos Co. stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
3/6/2025Q4 2024
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.20€0.20N/A€0.19€346.26 million€352.68 million
2/27/2025Q4 2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.49$0.49N/A$0.49$55.99 million$55.81 million
2/20/2025Q4 2024
Glaukos Co. stock logo
GKOS
Glaukos
-$0.38-$0.40-$0.02-$0.60$100.72 million$105.50 million
2/19/2025Q4 2024
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.23$0.25+$0.02-$0.01$1.26 billion$1.28 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.800.96%+13.30%40.40%14 Years
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.060.25%N/A11.76%1 Years

Latest LMAT, STVN, BLCO, and GKOS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
4/29/2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.201%5/15/20255/15/20255/29/2025
2/18/2025
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.200.9%3/13/20253/13/20253/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
Glaukos Co. stock logo
GKOS
Glaukos
0.19
5.54
4.71
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
N/A
7.74
5.52
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.81
1.21

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.76%
Glaukos Co. stock logo
GKOS
Glaukos
5.80%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
10.79%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.37 million351.94 millionOptionable
Glaukos Co. stock logo
GKOS
Glaukos
78057.14 million51.61 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
49022.59 million20.06 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
4,650302.84 million300.72 millionOptionable

Recent News About These Companies

William Blair Forecasts Reduced Earnings for Stevanato Group

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$11.86 -0.03 (-0.25%)
Closing price 05/13/2025 03:59 PM Eastern
Extended Trading
$11.65 -0.21 (-1.80%)
As of 08:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$92.21 -2.43 (-2.57%)
Closing price 05/13/2025 03:59 PM Eastern
Extended Trading
$92.00 -0.21 (-0.23%)
As of 08:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

LeMaitre Vascular stock logo

LeMaitre Vascular NASDAQ:LMAT

$83.28 +0.82 (+0.99%)
Closing price 05/13/2025 04:00 PM Eastern
Extended Trading
$83.16 -0.11 (-0.14%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€24.42 +0.76 (+3.21%)
As of 05/13/2025 03:52 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.